These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

148 related items for PubMed ID: 30655980

  • 21. Salivary Duct Carcinoma with Rhabdoid Features of the Parotid Gland with No E-Cadherin Expression: A Report with Anti-HER2 Therapy and Review of the Literature.
    Jain R, Sansoni ER, Angel J, Gleysteen JP, Hayes DN, Owosho AA.
    Dent J (Basel); 2023 Sep 25; 11(10):. PubMed ID: 37886914
    [Abstract] [Full Text] [Related]

  • 22. [Survival analysis and immunohistochemical study of HER-2 and AR (androgen receptor) expression in salivary duct carcinoma].
    Otsuka K, Imanishi Y, Habu N, Sato Y, Shigetomi S, Fujii R, Sakamoto K, Tomita T, Fujii M, Kameyama K, Ogawa K.
    Nihon Jibiinkoka Gakkai Kaiho; 2013 Sep 25; 116(9):1024-32. PubMed ID: 24191589
    [Abstract] [Full Text] [Related]

  • 23. Metastatic Salivary Duct Carcinoma with ERBB2 Amplification and Sequential Response to Ado-Trastuzumab Emtansine and Neratinib: A Case Report.
    Asper N, Roth KS, Hany TF, Salzberg SP, Tinguely M, Kadvany Y, Trojan A.
    Case Rep Oncol; 2023 Sep 25; 16(1):1500-1507. PubMed ID: 38033416
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Pleural metastasis from parotid secretory carcinoma: First report of morphology on effusion cytology, and role of pan-TRK immunohistochemistry.
    Mahendru R, Kakkar A, Cipriani NA, Sarma C, Ghosh V, Kaur K, Gupta S, Mohan A.
    Diagn Cytopathol; 2023 Jan 25; 51(1):E28-E37. PubMed ID: 36148935
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Salivary duct carcinoma cytologically diagnosed distinctly from salivary gland carcinomas with squamous differentiation.
    Kawahara A, Harada H, Akiba J, Kage M.
    Diagn Cytopathol; 2008 Jul 25; 36(7):485-93. PubMed ID: 18528886
    [Abstract] [Full Text] [Related]

  • 31. Loss of steroid hormone receptors is common in malignant pleural and peritoneal effusions of breast cancer patients treated with endocrine therapy.
    Schrijver WAME, Schuurman K, van Rossum A, Dutch Distant Breast Cancer Metastases Consortium, Peeters T, Ter Hoeve N, Zwart W, van Diest PJ, Moelans CB.
    Oncotarget; 2017 Aug 15; 8(33):55550-55561. PubMed ID: 28903441
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Intratumoral heterogeneity of HER2 protein and amplification of HER2 gene in salivary duct carcinoma.
    Kondo Y, Kikuchi T, Esteban JC, Kumaki N, Ogura G, Inomoto C, Hirabayashi K, Kajiwara H, Sakai A, Sugimoto R, Otsuru M, Okami K, Tsukinoki K, Nakamura N.
    Pathol Int; 2014 Sep 15; 64(9):453-9. PubMed ID: 25209856
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Salivary duct carcinoma with rhabdoid features: a salivary counterpart of pleomorphic lobular carcinoma of the breast.
    Kusafuka K, Kawasaki T, Maeda M, Yamanegi K, Baba S, Ito Y, Inagaki H, Nakajima T.
    Histopathology; 2017 Jan 15; 70(2):164-173. PubMed ID: 27079821
    [Abstract] [Full Text] [Related]

  • 36. Biomarker immunoprofile and molecular characteristics in salivary duct carcinoma: clinicopathological and prognostic implications.
    Santana T, Pavel A, Martinek P, Steiner P, Grossmann P, Baněčková M, Skálová A.
    Hum Pathol; 2019 Nov 15; 93():37-47. PubMed ID: 31437521
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Complete Response to Trastuzumab-Based Chemotherapy in a Patient with Human Epidermal Growth Factor Receptor-2-Positive Metastatic Salivary Duct Carcinoma ex Pleomorphic Adenoma.
    Kadowaki S, Yatabe Y, Hirakawa H, Komori A, Kondoh C, Hasegawa Y, Muro K.
    Case Rep Oncol; 2013 Nov 15; 6(3):450-5. PubMed ID: 24163659
    [Abstract] [Full Text] [Related]

  • 39. Frequent PTEN loss and differential HER2/PI3K signaling pathway alterations in salivary duct carcinoma: Implications for targeted therapy.
    Saintigny P, Mitani Y, Pytynia KB, Ferrarotto R, Roberts DB, Weber RS, Kies MS, Maity SN, Lin SH, El-Naggar AK.
    Cancer; 2018 Sep 15; 124(18):3693-3705. PubMed ID: 30289966
    [Abstract] [Full Text] [Related]

  • 40. [Effective treatment by both anti-androgen therapy and chemotherapy for a patient with advanced salivary duct carcinoma].
    Kuroda H, Sakurai T, Yamada M, Uemura N, Ono M, Abe T, Fujii S, Maeda M, Kohda K, Obata M, Ando M, Iyama S, Kato J.
    Gan To Kagaku Ryoho; 2011 Apr 15; 38(4):627-30. PubMed ID: 21498992
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.